



*Angiotensin Therapeutics Inc. is a privately held biopharmaceutical company focused on developing breakthrough therapies for COVID 19 and other potential Coronavirus outbreaks as well as for treatment of Kidney Disease*

We are studying shorter forms of a naturally occurring enzyme called Angiotensin Converting Enzyme 2 (ACE2) for their use to treat kidney disease. We are modifying its therapeutic window to increase its duration of action from hours to days, making it a more attractive therapeutic intervention for patients and doctors.

Furthermore, we discovered a transformative application of our enzyme variant for treating COVID-19, with our ongoing preclinical studies showing promise. COVID-19 has devastated the world today and has very limited therapeutic options. As ACE2 is the **receptor** of coronavirus entry into cells, our approach is based on intercepting the virus from reaching the ACE2 receptor in the cell membranes. Even with the expected availability of effective vaccines in 2021, there will remain a need for prevention and treatment for people that either do not get the vaccine or were not totally protected. Moreover, other coronaviruses may likely emerge in the coming years causing similar problems as seen today with COVID-19.

By developing a therapeutic intervention for COVID 19 and the family of coronaviruses or Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD), we are addressing enormous market opportunities, in excess of hundreds of billion dollar and lifesaving therapies, in excess of hundreds of millions lives.

We are working in collaboration with established investigators at Northwestern University to drive the execution of our development plan. This research is based on the laboratory work of well-known scientist and kidney specialist, Dr. Daniel Batlle and the application of a biologic variant of the enzyme ACE2 designed for better pharmacodynamics and therapeutic benefits. We are uniquely prepared with the medical professionals and scientists to bring cutting edge treatments to the mainstream. Our mission is to develop lifesaving treatments.

### Compelling Investment Opportunity in Initial Seed Round

- Successful alteration to a known endogenous enzyme (ACE2) with its established safety profile for new and expanded therapeutic applications
- Addressing huge unmet therapeutic needs in COVID 19 and Kidney Disease
- Potential focused markets in multi-billion dollar range
- De-risked development program with lead molecule likely safe as current native molecule and its corresponding limited therapeutic window is in clinical trials
- Long-life IP licensed from Northwestern University
- Rapidly advancing to clinical validation in these new therapeutic indications including toxicology experiments with likely minimal risk
- Preclinical demonstration in relevant models of kidney disease ➤ Established academic collaborations with virology laboratories
- Experienced management team with scientific, drug development and capital market experience
- Major non-dilutive funding programs are accessible
- Short timelines to development partnerships
- Low seed valuation and managed capital gets to significant accretive clinical trials stage



## **Minimal Capital Investment to Achieve Multiple Significant Value Inflection Points**

### **Expansion into COVID-19 Therapeutic Race, Exploring Approval Applications, Non-Dilutive Funding and Achieving IND needed regulations**

Collaborate with Institutions to assess the biologically active targeted receptor to impede COVID-19 Spike Protein binding to the cell membrane ACE2 receptor and other protective mechanisms of action

Exploring Government sponsored alliances (BARDA, DARPA, DOD), NGO-contracts, and Managed Capital to POC for Strategic Development

### **AKI & CKD Therapeutic Need Presents High Value Multi-Billion Dollar Opportunity**

Engaging in strategic partnership discussions to Leading Pharmaceutical Companies and Pursuing Managed Capital towards Clinical Data to enhance potential value of platform

### **Historical and Growing Trend of Significant “Big Pharma Deals” at Preclinical Stage or Following POC Data**

Embark on de-risked capital plan for clinical development program

#### **COVID-19:**

ACE2 is a critical receptor for SARS-CoV-<sup>1</sup> infection. Thus, we are currently testing the potential use of our soluble ACE2 variants to competitively bind and intercept the coronavirus from infecting models of COVID-19. We recently described the hypothesis and rationale for the therapeutic application of soluble ACE2 to treat SARS-CoV-2 (Batlle *et al.*, Clinical Science and Hypertension 2020.)

#### **Kidney Diseases:**

We have bioengineered and tested short variants of ACE2 whereas our preclinical studies show better kidney delivery via glomerular filtration and showed efficacy in a mouse model of AKI. These findings were presented at the November 2019 meeting of the American Society of Nephrology. The administration of our short ACE2 variants leads to more formation of Angiotensin 1-7 by the kidneys. Preventing undesirable angiotensin II accumulation and promoting formation of Angiotensin 1-7 is the likely mechanism that protects against the kidney damage seen in AKI and CKD. A distinctive finding is that with administration of our ACE2-based compounds blood pressure may not fall, whereas the widely used RAS blockers (ACE inhibitors and Angiotensin receptor blockers) may cause hypotension and hyperkalemia.

### **WE ARE SEEKING FUNDING TO PROGRESS OUR PRE-CLINICAL EFFORTS TO FILE AN INVESTIGATIVE NEW DRUG APPLICATION (IND) AND ENTER INTO CLINICAL TRIALS**

For Further Information, please contact:

Dr. Cory Gutterman  
Interim CEO  
Angiotensin Therapeutics  
[Cory@Angiotx.com](mailto:Cory@Angiotx.com)

Dr. Daniel Batlle  
CSO & Founder,  
Angiotensin Therapeutics  
[Daniel@Angiotx.com](mailto:Daniel@Angiotx.com)